Analyst Price Targets — INNV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 8, 2023 8:02 am | — | J.P. Morgan | $8.00 | $7.50 | Benzinga | JP Morgan Maintains Neutral on InnovAge Holding, Raises Price Target to $8 |
| November 23, 2022 9:34 am | — | Goldman Sachs | $8.00 | $6.80 | Benzinga | Goldman Sachs Maintains Neutral on InnovAge Holding, Raises Price Target to $8 |
| November 16, 2022 7:53 am | — | Citigroup | $8.00 | $7.25 | Benzinga | Citigroup Maintains Neutral on InnovAge Holding, Raises Price Target to $8 |
| September 15, 2022 7:13 am | — | Barclays | $5.00 | $4.94 | Benzinga | Barclays Maintains Equal-Weight on InnovAge Holding, Lowers Price Target to $5 |
| April 20, 2022 6:08 am | — | Piper Sandler | $5.00 | $6.59 | Benzinga | Piper Sandler Downgrades InnovAge Holding to Underweight, Raises Price Target to $5 |
Latest News for INNV
LRN's surge, INNV's upgrade-driven rally and PEP's steady gains showcase how Zacks strategies are outperforming despite ongoing market volatility.
NWPX, INNV, WGS, BCBP and BWXT have been added to the Zacks Rank #1 (Strong Buy) List on March 18, 2026.
BTSG, INNV and PACS could benefit as the medical services industry embraces digital health and analytics, though workforce shortages still pressure providers.
InnovAge (INNV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
InnovAge (INNV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INNV.
U.S. House Trading
No House trades found for INNV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.